Navigation Links
Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
Date:12/5/2008

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two of the studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Following are details for each embargoed session (all times are Central Standard Time):

    -- Thursday, December 11, 2008, 4 p.m. - 4:15 p.m.
       Abstract #25
       Oral presentation (General Session 2): "GRB7-dependent pathways are
       potential therapeutic targets in triple-negative breast cancer"
       Presenter: Joseph Sparano, M.D., Montefiore-Einstein Cancer Center, New
       York
       Location: Exhibit Hall D

    -- Friday, December 12, 2008, 7 a.m. - 9 a.m.
       Abstract #2066
       Poster presentation (Poster Session II: Prognosis and Response
       Predictions: Biomarkers -- Methods): "Quantitative gene expression
       analysis using Oncotype DX in ductal carcinoma in situ that is adjacent
       to invasive ductal carcinoma"
       Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer
       Center at the University of California, San Francisco
       Location: Exhibit Hall B

    -- Friday, December 12, 2008, 5 p.m. - 7 p.m.
       Abstract #3049
       Poster presentation (Poster Session III: Tumor Cell and Molecular
       Biology: Hormonal Factors and Receptors): "Associations between
       estrogen receptor (ER) Alpha expression levels and ER genotypes"
       Presenter: Daniel Hayes, M.D., University of Michigan Health System,
       Ann Arbor
       Location: Exhibit Hall B

    -- Saturday, December 13, 2008, 10 a.m. - 10:15 a.m.
       Abstract #53
       Oral presentation (General Session 5): "Risk of distant recurrence
       using Oncotype DX in postmenopausal primary breast cancer patients
       treated with anastrozole or tamoxifen: a TransATAC study"
       Presenter: Mitch Dowsett, Ph.D., Royal Marsden Hospital, London
       Location: Exhibit Hall D

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. Oncotype DX has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
2. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Genomic Health to Present at Stephens Fall Investment Conference
6. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
7. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
8. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. /C O R R E C T I O N -- Rosetta Genomics Ltd/
10. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today ... via 510(k) for sale in the United States. These components expand the capabilities ... With one-level sales beginning in October of 2015, the company has seen significant ...
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and ... named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... needs of end users facing some of the most complex data challenges in the ...
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
Breaking Biology News(10 mins):